期刊文献+

胃癌新辅助化疗后完全腔镜全胃切除术安全性与短期疗效观察

Safety and short-term efficacy comparison of laparoscopic total gastrectomy after neoadjuvant chemotherapy for gastric cancer
下载PDF
导出
摘要 目的:比较进展期胃癌新辅助化疗(NACT)后行完全腹腔镜全胃切除术(TLTG)与腹腔镜辅助全胃切除术(LATG)的安全性和短期疗效。方法:回顾性分析2015年1月—2023年8月在北京大学深圳医院胃肠外科收治的73例行NACT的胃癌患者的临床资料。按是否进行腹腔内消化道重建分为TLTG组(n=31)和LATG组(n=42)。收集并比较两组患者的基本资料、短期临床疗效(包括手术相关指标、并发症和术后恢复指标)。结果:TLTG组TLTG组术中出血量及术后第1天引流量、WBC少于LATG组,腹部手术切口小于LATG组,术后首次排气时间、首次进流食时间均早于LATG组,术后第3天VAS评分低于LATG组,手术时间及术后住院时间短于LATG组,差异有统计学意义(P<0.05)。NACT后,两组的淋巴结清扫总数、阳性淋巴结数目、经治疗后病理分期、原发肿瘤病理分期、淋巴结病理分期、病理治疗反应分级、肿瘤分化程度、Lauren分型、首次下床活动时间、排便时间、引流管拔管时间、术后第3天WBC、术后3d血红蛋白水平、术后3d白蛋白水平、术后并发症比较,差异均无统计学意义(P>0.05)。结论:相较于LATG,TLTG术后恢复更快、术中出血量更少、手术切口更短、手术时间更短,安全性较好。 Objective To compare the safety and short-term efficacy differences between totally laparoscopic total gastrectomy(TLTG)and laparoscopic-assisted total gastrectomy(LATG)after neoadjuvant chemotherapy for advanced gastric cancer.Methods Clinical data of 73 patients with gastric cancer who underwent neoadjuvant chemotherapy at the Department of Gastrointestinal Surgery,Peking University Shenzhen Hospital from January 2015 to August 2023 were retrospectively analyzed.Patients were divided into TLTG group(n=31)and LATG group(n=42)based on whether intracorporeal digestive tract reconstruction was performed.Baseline characteristics and short-term clinical outcomes(including surgical-related parameters,complications,and postoperative recovery indicators)were collected and compared between the two groups.Results The intraoperative blood loss,drainage volume and white blood cell count(WBC)on the first day after operation in TLTG group were less than those in LATG group.The abdominal incision in TLTG group was smaller than that in LATG group.The first exhaust time and first liquid diet time after operation in TLTG group were earlier than those in LATG group.The VAS score on the third day after operation in TLTG group was lower than that in LATG group.The operation time and postoperative hospital stay in TLTG group were shorter than those in LATG group(P<0.05).There were no significant differences between the two groups in terms of total number of lymph nodes retrieved,number of positive lymph nodes,post-therapy TNM staging,primary tumor pathologic staging,lymph node pathologic staging,tumor regression grade,tumor differentiation,Lauren classification,time to first ambulation,time to first bowel movement,time to removal of drainage tube,WBC on postoperative day 3,hemoglobin level on postoperative day 3,albumin level on postoperative day 3,and postoperative complications(P>0.05).Conclusions Compared to LATG,TLTG is associated with faster postoperative recovery,less intraoperative blood loss,shorter abdominal incision,and shorter operation time,but it does not demonstrate a significant advantage in terms of complication rates.
作者 马亚辉 吕国庆 MA Yahui;LYU Guoqing(College of Clinical,Peking University Shenzhen Hospital,Anhui Medical University,Shenzhen,Guangdong 518036,China;Department of Gastrointestinal Surgery,Peking University Shenzhen Hospital,Shenzhen,Guangdong 518036,China;College of the Fifth Clinical Medical,Anhui Medical University,Hefei,Anhui 230032,China)
出处 《医药前沿》 2024年第14期7-12,16,共7页 Journal of Frontiers of Medicine
基金 广东省深圳市三名工程项目(SZSM201612051)。
关键词 胃癌 新辅助化疗 完全腹腔镜全胃切除术 腹腔镜辅助全胃切除术 短期疗效 Gastric cancer Neoadjuvant chemotherapy Totally laparoscopic total gastrectomy Laparoscopic-assisted total gastrectomy Short-term outcomes
  • 相关文献

参考文献7

二级参考文献53

  • 1Keishiro Aoyagi,Kikuo Kouhuji,Motoshi Miyagi,Takuya Imaizumi,Junya Kizaki,Kazuo Shirouzu.Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy[J].World Journal of Hepatology,2010,2(2):81-86. 被引量:27
  • 2Jun-Jie Xiong,Kiran Altaf,Muhammad A Javed,Quentin M Nunes,Wei Huang,Gang Mai,Chun-Lu Tan,Rajarshi Mukherjee,Robert Sutton,Wei-Ming Hu,Xu-Bao Liu.Roux-en-Y versus BillrothⅠreconstruction after distal gastrectomy for gastric cancer:A meta-analysis[J].World Journal of Gastroenterology,2013,19(7):1124-1134. 被引量:34
  • 3Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malig- nancies[J]. SeminOncol, 2004, 31(4):450-464.
  • 4Siewert JR, Feith M, Stein HJ. Biologic and clinical variations of ade- nocarcinoma at the esophago-gastric junction: relevance of a topo- graphic- anatomic subclassification[J]. J Surg Oncol, 2005, 90(3): 139-146.
  • 5Kurokawa Y, Sasako M, Doki Y. Treatment approaches to esophago- gastric junction tumors[J]. Dig Surg, 2013, 30(2):169-173.
  • 6Pepek JM, Chino JP, Willett CO, et al. Preoperative chemoradiotherapy for locally advanced gastric cancer[J]. Radiat Oncol, 2013, 8:6.
  • 7Lawrence TS, Blackstock AW, McGinn C. The mechanism of action of radiosensitization of conventional chemotherapeutic agents[J]. Semin Radiat Oncol, 2003, 13(1):13-21.
  • 8van Hagen P, Hulshof MC, van lanschot J J, et al. Preoperative chemoradiotherapy for esophageal or junctionaJ cancer[J]. N Engl J Med, 2012, 366(22]:2074-2084.
  • 9Stahl M, Walz MK, Stuschke M, et al. Phase Ⅲ comparison of pre-operative chemotherapy compared with chemoradiotherapy in pa- tients with locally advanced adenocardnoma of the esophagogas- tric junction[J]. J Clin Oncol, 2009, 27(6):851-856.
  • 10Ronellenfitsch U, Schwarzbach M, Hofheinz R, et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data[J]. Eur J Cancer, 2013, 49(15): 3149-3158.

共引文献219

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部